StreetInsider.com News Articles

Form 4 Imunon, Inc. For: May 22 Filed by: Tardugno Michael H

Wed, 27 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260527/26558225.html

Form 4 Imunon, Inc. For: May 22 Filed by: Tardugno Michael H

Wed, 27 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260527/26558225.html

Form 4 Imunon, Inc. For: May 22 Filed by: Dentzer James E

Wed, 27 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260527/26557995.html

Form 4 Imunon, Inc. For: May 22 Filed by: Dentzer James E

Wed, 27 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260527/26557995.html

Form 4 Imunon, Inc. For: May 22 Filed by: Pellizzari Christine A

Wed, 27 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260527/26558003.html

Form 4 Imunon, Inc. For: May 22 Filed by: Pellizzari Christine A

Wed, 27 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260527/26558003.html

Form 4 Imunon, Inc. For: May 22 Filed by: Fritz Frederick J.

Wed, 27 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260527/26557972.html

Form 4 Imunon, Inc. For: May 22 Filed by: Fritz Frederick J.

Wed, 27 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260527/26557972.html

Form 4 Imunon, Inc. For: May 22 Filed by: Braun Donald P

Wed, 27 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260527/26557982.html

Form 4 Imunon, Inc. For: May 22 Filed by: Braun Donald P

Wed, 27 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260527/26557982.html

Form 4 Imunon, Inc. For: May 22 Filed by: Lindborg Stacy

Wed, 27 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260527/26557961.html

Form 4 Imunon, Inc. For: May 22 Filed by: Lindborg Stacy

Wed, 27 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260527/26557961.html

Form SCHEDULE 13G/A Imunon, Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 15 May 2026 11:22:00 -0400

si-local-file:///var/storage/secattach/20260515/26502118.html

Form SCHEDULE 13G/A Imunon, Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 15 May 2026 11:22:00 -0400

si-local-file:///var/storage/secattach/20260515/26502118.html

Imunon (IMNN) Misses Q1 EPS by 84c

Tue, 12 May 2026 08:48:49 -0400

Imunon (NASDAQ: IMNN) reported Q1 EPS of ($0.84).

For earnings history and earnings-related data on Imunon (IMNN) click here.

Form 10-Q Imunon, Inc. For: Mar 31

Tue, 12 May 2026 08:46:00 -0400

si-local-file:///var/storage/secattach/20260512/26473952.html

Form 10-Q Imunon, Inc. For: Mar 31

Tue, 12 May 2026 08:46:00 -0400

si-local-file:///var/storage/secattach/20260512/26473952.html

Form 8-K Imunon, Inc. For: May 12

Tue, 12 May 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260512/26473478.html

Form 8-K Imunon, Inc. For: May 12

Tue, 12 May 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260512/26473478.html

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

Tue, 12 May 2026 08:00:00 -0400

IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer

Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement

FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing

Company to hold conference call today at 11:00 a.m. ET

LAWRENCEVILLE, N.J., May 12, 2026 (GLOBE NEWSWIRE) --

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

Tue, 12 May 2026 08:00:00 -0400

IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer

Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement

FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing

Company to hold conference call today at 11:00 a.m. ET

LAWRENCEVILLE, N.J., May 12, 2026 (GLOBE NEWSWIRE) --

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

Tue, 12 May 2026 08:00:00 -0400

IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer

Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement

FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing

Company to hold conference call today at 11:00 a.m. ET

LAWRENCEVILLE, N.J., May 12, 2026 (GLOBE NEWSWIRE) --

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

Tue, 12 May 2026 08:00:00 -0400

IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer

Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement

FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing

Company to hold conference call today at 11:00 a.m. ET

LAWRENCEVILLE, N.J., May 12, 2026 (GLOBE NEWSWIRE) --

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

Tue, 05 May 2026 08:30:00 -0400

LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, May 12, 2026 to discuss financial results for the first quarter ended March 31, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer.

To participate in the

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

Tue, 05 May 2026 08:30:00 -0400

LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, May 12, 2026 to discuss financial results for the first quarter ended March 31, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer.

To participate in the